A new study presented at the American Society of Hematology (ASH) 2020 Annual Meeting this weekend showed measurable residual disease (MRD) assessments may better inform therapy decision-making in patients with multiple myeloma. The retrospective trial, presented by an international team of US and Spain investigators, showed that therapy changes based on MRD resulted in prolonged progression-free survival in patients with multiple myeloma versus control. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more